ZEPBOUND

Aug 09, 2024

More than 80 obesity drugs are currently in the pipeline with a strong emphasis on GLP-1 receptor agonists. Glucagon-like peptide-1 (GLP-1) receptor agonists are medications designed to treat type 2 diabetes mellitus and obesity by reducing blood glucose levels and regulating metabolism. Ongoing efforts by several ...

Aug 02, 2024

With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...

Jun 28, 2024

Obesity ranks as the second leading cause of preventable death, linked to the risk of inflammatory conditions that are directly and indirectly related to cardiovascular disease, diabetes, respiratory issues, psychological problems, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. This poses a majo...